(lp0
S"What is Behind XOMA Corporation's  Superior ROE? Simply Wall St - Mar 16, 2017 XOMA Corporation  delivered 35.4% ROE in the last year. However, to put XOMA's Return on Equity in perspective, we must compare it to the performance of its industry, which averaged an ROE of 27.46%.Stock Returns: Enzymotec Ltd.  is Beating XOMA Corporation ... - CML NewsXOMA Corporation  To Release Earnings - UK Market News"
p1
aS'Buy XOMA Corporation For Its Monoclonal Antibodies To Treat Congenital ... Seeking Alpha - Jul 24, 2016 XOMA Corporation is an emerging biotechnology company with proprietary monoclonal antibody development technology that has attracted collaborations with large companies like Novartis and Novo Nordisk.'
p2
aS'XOMA Announces up to $22 Million Generated from Sale of Royalty Streams from ... GlobeNewswire  - Dec 21, 2016 BERKELEY, Calif., Dec. 21, 2016  -- XOMA Corporation , a leader in the discovery and development of therapeutic antibodies, today announced several corporate actions to further streamline its operations to focus on&nbsp;...'
p3
aS"Xoma Corp Trading Well Above Recent Offering Price But Below October Reverse ... Benzinga - Feb 13, 2017 XOMA Corporation  shares are trading higher by $0.70  at $4.73 in Monday's session. The issue bottomed at its higher opening tick of $4.30 and has continued to move higher.XOMA prices $25M direct equity offering - Seeking AlphaXOMA Corporation  Stock: Gaining On Offering Pricing - CNA Finance "
p4
aS"3 Things You Need to Know About XOMA Corp. Motley Fool - Mar 26, 2015 XOMA's product pipeline consists of human and humanized monoclonal antibodies designed to treat metabolic, inflammatory, and cardiovascular diseases."
p5
aS'XOMA Ltd: Odds Improving On This $1 Biotech Lottery Ticket Seeking Alpha - Oct 3, 2015 XOMA Corporation is a late-stage biotechnology company with expertise in allosteric modulation and a portfolio of innovative therapeutic monoclonal antibodies.'
p6
aS'XOMA to Announce Fourth Quarter and Full Year 2016 Financial Results and Host ... GlobeNewswire  - Mar 14, 2017 BERKELEY, Calif., March 14, 2017  -- XOMA Corporation , a pioneer in the discovery and development of therapeutic antibodies, announced today it will issue its fourth quarter and full year 2016 financial results before&nbsp;...'
p7
aS'XOMA Appoints Matthew Perry to its Board of Directors GlobeNewswire  - Feb 16, 2017 BERKELEY, Calif., Feb. 16, 2017  -- XOMA Corporation , a leader in the discovery and development of therapeutic antibodies, today announced the appointment of Matthew Perry, President of BVF Partners L.P.'
p8
aS"XOMA Announces Reverse Stock Split GlobeNewswire  - Oct 14, 2016 BERKELEY, Calif., Oct. 14, 2016  -- XOMA Corporation , a leader in the discovery and development of therapeutic antibodies, today announced that, at a special meeting of the Company's stockholders held on October 14&nbsp;..."
p9
aS'XOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies GlobeNewswire  - Sep 15, 2016 BERKELEY, Calif., Sept. 15, 2016  -- XOMA Corporation , a leader in the discovery and development of therapeutic antibodies, provided an update on its ongoing XOMA 358 Phase 2 studies in patients with severe&nbsp;...XOMA  Updates on XOMA 358 Phase 2; PBS Study Showed Some Effect on ... - StreetInsider.com'
p10
a.